Nuvectis Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	35.44	18.53	19.13	19.99	5.74	-
Cash & Short-Term Investments	35.44	18.53	19.13	19.99	5.74	-
Cash Growth	106.43%	-3.10%	-4.34%	248.19%	-	-
Other Current Assets	0.15	0.07	0.06	0.41	0.09	-
Total Current Assets	35.59	18.61	19.19	20.41	5.83	-
Long-Term Deferred Charges	-	-	-	-	0.82	-
Total Assets	35.59	18.61	19.19	20.41	6.66	-
Accounts Payable	6.44	2.5	2.77	2.91	1.06	0.01
Accrued Expenses	5.06	6.4	4.21	2.83	0.54	-
Other Current Liabilities	0.08	-	-	0.45	0.82	-
Total Current Liabilities	11.58	8.89	6.98	6.19	2.42	0.01
Total Liabilities	11.58	8.89	6.98	6.19	2.42	0.01
Additional Paid-In Capital	116.38	82.96	66.45	46.2	1.89	-
Retained Earnings	-92.37	-73.25	-54.25	-31.99	-12.9	-0.01
Total Common Equity	24.01	9.71	12.2	14.22	-11.01	-0.01
Shareholders' Equity	24.01	9.71	12.2	14.22	4.24	-0.01
Total Liabilities & Equity	35.59	18.61	19.19	20.41	6.66	-
Net Cash (Debt)	35.44	18.53	19.13	19.99	5.74	-
Net Cash Growth	106.43%	-3.10%	-4.34%	248.19%	-	-
Net Cash Per Share	1.73	1.08	1.23	1.58	1.35	-
Filing Date Shares Outstanding	25.61	23.39	17.77	14.75	12.72	3.9
Total Common Shares Outstanding	25.64	19.5	17.42	14.64	4.51	3.9
Working Capital	24.01	9.71	12.2	14.22	3.41	-0.01
Book Value Per Share	0.94	0.50	0.70	0.97	-2.44	-0.00
Tangible Book Value	24.01	9.71	12.2	14.22	-11.01	-0.01
Tangible Book Value Per Share	0.94	0.50	0.70	0.97	-2.44	-0.00

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q